A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease

Yu, Margaret; Bega, Danny

doi:10.7916/tohm.v0.678

Cited by 5 publications

(1 citation statement)

References 67 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Fifteen records were excluded (Amato et al, 2017;Bahji, Meyyappan, & Hawken, 2020;Davis, 2008;Fife, Moawad, Moschonas, Shepard, & Hammond, 2015;Gouveia, Guimarães, Santos, & Quintans-Júnior, 2019;Hasheminasab, Tajadini, & Setayesh, 2020;Kumar, Datta, Wright, Furtado, & Russell, 2013;Maldonado, Pinz on, & Martínez, 2010;Marshall & Rathbone, 2011;Meyer et al, 2010;Mücke et al, 2016;Mun et al, 2020;Orsolini et al, 2019;Torres-Moreno & Farré, 2015;Yu & Bega, 2019);…”

Section: Search Resultsmentioning

confidence: 99%

Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews

Riera

Pacheco

Bagattini

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

The debate on the use of cannabinoids for therapeutic purposes is constantly on the rise. This overview aimed to map the evidence on the therapeutic effects of cannabis derivatives and their synthetic analogs. Systematic reviews (SRs) of randomized trials were identified through a comprehensive search in several databases, and their methodological quality were evaluated with AMSTAR‐2. The results for main outcomes are presented, prioritizing those from updated and better quality SRs. Finally, 68 SRs, addressing 37 different health conditions, were included. The methodological quality was high for eight SRs. The evidence certainty (GRADE) for the effects of cannabinoids is not high for any of the outcomes identified. Evidence certainty was moderate for the following: (a) cannabidiol appears to be beneficial for quality of life but increases the risk of adverse events in ulcerative colitis; (b) cannabinoids in general appear to have no clinically important benefit for chronic non‐oncologic pain, spasticity‐related pain in multiple sclerosis, or for acute post‐operative pain; (c) cannabinoids in general appear to have a benefit in reducing chemotherapy‐related nausea and vomiting. For all other outcomes from remaining comparisons, the evidence certainty was low, very low, or not evaluated, which prevents recommendations for or against their routine use.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews

Riera

Pacheco

Bagattini

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

Islam,

Jony,

Thufa

et al. 2023

Mol Neurobiol

View full text Add to dashboard Cite

Cognition-oriented treatments and physical exercise on cognitive function in Huntington’s disease: Protocol for systematic review

Huynh¹,

Nategh²,

Jamadar

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: Cognitive impairments are prevalent in Huntington's disease (HD), occurring many years prior to clinical diagnosis and are the most impactful on quality of life of patients. Cognitive interventions and exercise have been found to be efficacious in improving cognitive function in several clinical populations (e.g., older adults with mild cognitive impairment and dementia). However, the utility of cognitive interventions has not been systematically reviewed in HD. This systematic review aims to examine the efficacy of cognitive and physical interventions on cognitive function in HD. Methods: Electronic databases (MEDLINE, EMBASE, PsycINFO, CENTRAL) were searched through till 10 May 2021 for interventional studies investigating the effect of cognition-oriented treatments and physical exercise on cognitive function in individuals with HD, compared to any control or no control. The primary outcome is change on objective measures of cognition. Additional outcomes include change in psychosocial, functional and neuroimaging measures. Variations of effects based on population and study factors will be considered. Risk of bias will be assessed using the Cochrane RoB 2 tool and ROBINS-I tool. Where appropriate, outcomes will be pooled using random-effects meta-analyses, heterogeneity will be examined using tau2 and I2 statistics, and moderators will be examined using meta-regression models. Discussion: This review will systematically evaluate the efficacy of cognitive and physical interventions on improving cognitive function in HD. The eligibility criteria and planned analyses will allow for a comprehensive assessment of certainty in the evidence that will inform future trials and clinical practice. Registration: This protocol was registered on PROSPERO (CRD42021259152).

show abstract

A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease

Cited by 5 publications

References 67 publications

Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews

Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews

A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

Cognition-oriented treatments and physical exercise on cognitive function in Huntington’s disease: Protocol for systematic review

Contact Info

Product

Resources

About